Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 107945, 10 pages
http://dx.doi.org/10.1155/2012/107945
Review Article

Caroli's Disease: Current Knowledge of Its Biliary Pathogenesis Obtained from an Orthologous Rat Model

Department of Human Pathology, Graduate School of Medicine, Kanazawa University, Kanazawa 920-8640, Japan

Received 23 March 2011; Accepted 7 April 2011

Academic Editor: Yoshiyuki Ueno

Copyright © 2012 Yasunori Sato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Nakanuma, T. Terada, G. Ohta, M. Kurachi, and F. Matsubara, “Caroli's disease in congenital hepatic fibrosis and infantile polycystic disease,” Liver, vol. 2, no. 4, pp. 346–354, 1982. View at Google Scholar · View at Scopus
  2. Y. Nakanuma, K. Harada, Y. Sato, and H. Ikeda, “Recent progress in the etiopathogenesis of pediatric biliary disease, particularly Caroli's disease with congenital hepatic fibrosis and biliary atresia,” Histology and Histopathology, vol. 25, no. 2, pp. 223–235, 2010. View at Google Scholar · View at Scopus
  3. P. C. Harris and V. E. Torres, “Polycystic kidney disease,” The Annual Review of Medicine, vol. 60, pp. 321–337, 2009. View at Google Scholar
  4. M. Adeva, M. El-Youssef, S. Rossetti et al., “Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD),” Medicine, vol. 85, no. 1, pp. 1–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. V. J. Desmet, “Congenital diseases of intrahepatic bile ducts: variations on the theme “ductal plate malformation”,” Hepatology, vol. 16, no. 4 I, pp. 1069–1083, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Roskams and V. Desmet, “Embryology of extra- and intrahepatic bile ducts, the ductal plate,” Anatomical Record, vol. 291, no. 6, pp. 628–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Onori, A. Franchitto, R. Mancinelli et al., “Polycystic liver diseases,” Digestive and Liver Disease, vol. 42, no. 4, pp. 261–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. S. Williams, P. Cobo-Stark, L. R. James, S. Somlo, and P. Igarashi, “Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease,” Pediatric Nephrology, vol. 23, no. 5, pp. 733–741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. R. Gallagher, E. L. Esquivel, T. S. Briere et al., “Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1,” American Journal of Pathology, vol. 172, no. 2, pp. 417–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. R. Woollard, R. Punyashtiti, S. Richardson et al., “A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation,” Kidney International, vol. 72, no. 3, pp. 328–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Moser, S. Matthiesen, J. Kirfel et al., “A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD),” Hepatology, vol. 41, no. 5, pp. 1113–1121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Garcia-Gonzalez, L. F. Menezes, K. B. Piontek et al., “Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway,” Human Molecular Genetics, vol. 16, no. 16, pp. 1940–1950, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Sanzen, K. Harada, M. Yasoshima, Y. Kawamura, M. Ishibashi, and Y. Nakanuma, “Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis,” American Journal of Pathology, vol. 158, no. 5, pp. 1605–1612, 2001. View at Google Scholar · View at Scopus
  14. O. Yonem and Y. Bayraktar, “Clinical characteristics of Caroli's syndrome,” World Journal of Gastroenterology, vol. 13, no. 13, pp. 1934–1937, 2007. View at Google Scholar · View at Scopus
  15. N. Kerkar, K. Norton, and F. J. Suchy, “The hepatic fibrocystic diseases,” Clinics in Liver Disease, vol. 10, no. 1, pp. 55–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Torra, C. Badenas, A. Darnell, C. Brú, A. Escorsell, and X. Estivill, “Autosomal dominant polycystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation rapid communication,” Kidney International, vol. 52, no. 1, pp. 33–38, 1997. View at Google Scholar · View at Scopus
  17. R. Madjov, P. Chervenkov, V. Madjova, and B. Balev, “Caroli's disease. Report of 5 cases and review of literature,” Hepato-Gastroenterology, vol. 52, no. 62, pp. 606–609, 2005. View at Google Scholar · View at Scopus
  18. U. Dagli, F. Atalay, N. Şaşmaz, S. Bostanoǧlu, G. Temuçin, and B. Şahin, “Caroli's disease: 1977–1995 experiences,” European Journal of Gastroenterology and Hepatology, vol. 10, no. 2, pp. 109–112, 1998. View at Google Scholar · View at Scopus
  19. S. Totkas and P. Hohenberger, “Cholangiocellular carcinoma associated with segmental Caroli's disease,” European Journal of Surgical Oncology, vol. 26, no. 5, pp. 520–521, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Yamato, M. Sasaki, M. Hoso et al., “Intrahepatic cholangiocarcinoma arising in congenital hepatic fibrosis: report of an autopsy case,” Journal of Hepatology, vol. 28, no. 4, pp. 717–722, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Nakanuma, M. Sasaki, Y. Sato, X. Ren, H. Ikeda, and K. Harada, “Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts,” World Journal of Hepatology, vol. 1, pp. 35–42, 2009. View at Google Scholar
  22. M. J. Payan, R. Choux, J. Sahel et al., “Caroli's disease associated with pancreatic heterotopia and biliary papillomatosis,” Histopathology, vol. 9, pp. 1001–1006, 1985. View at Google Scholar
  23. L. Fabris, M. Cadamuro, R. Fiorotto et al., “Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases,” Hepatology, vol. 43, no. 5, pp. 1001–1012, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Gaudio, B. Barbaro, D. Alvaro et al., “Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism,” Gastroenterology, vol. 130, no. 4, pp. 1270–1282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. U. Becker, A. Opazo Saez, K. Zerres et al., “The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease,” Kidney and Blood Pressure Research, vol. 33, no. 2, pp. 129–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. O. Lee, T. Masyuk, P. Splinter et al., “MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease,” Journal of Clinical Investigation, vol. 118, no. 11, pp. 3714–3724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Yasoshima, Y. Sato, S. Furubo et al., “Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease,” Journal of Pathology, vol. 217, no. 3, pp. 442–451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ozaki, Y. Sato, M. Yasoshima, K. Harada, and Y. Nakanuma, “Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis,” Liver International, vol. 25, no. 4, pp. 817–828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. W. J. Miller, A. G. Sechtin, W. L. Campbell, and P. C. Pieters, “Imaging findings in Caroli's disease,” American Journal of Roentgenology, vol. 165, no. 2, pp. 333–337, 1995. View at Google Scholar · View at Scopus
  30. T. Asselah, O. Ernst, G. Sergent, C. L'Herminé, and J. C. Paris, “Caroli's disease: a magnetic resonance cholangiopancreatography diagnosis,” American Journal of Gastroenterology, vol. 93, no. 1, pp. 109–110, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. A. N. Ananthakrishnan and K. Saeian, “Caroli's disease: identification and treatment strategy,” Current Gastroenterology Reports, vol. 9, no. 2, pp. 151–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Levy, C. A. Rohrmann, L. A. Murakata, and G. J. Lonergan, “Caroli's disease: radiologic spectrum with pathologic correlation,” American Journal of Roentgenology, vol. 179, no. 4, pp. 1053–1057, 2002. View at Google Scholar · View at Scopus
  33. J. Y. Mabrut, C. Partensky, D. Jaeck et al., “Congenital intrahepatic bile duct dilatation is a potentially curable disease: long-term results of a multi-institutional study,” Annals of Surgery, vol. 246, no. 2, pp. 236–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Ros, S. Navarro, C. Bru, R. Gilabert, L. Bianchi, and M. Bruguera, “Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli's syndrome,” Lancet, vol. 342, no. 8868, pp. 404–406, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. W. T. Kassahun, T. Kahn, C. Wittekind et al., “Caroli's disease: liver resection and liver transplantation. Experience in 33 patients,” Surgery, vol. 138, no. 5, pp. 888–898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Millwala, D. L. Segev, and P. J. Thuluvath, “Caroli's disease and outcomes after liver transplantation,” Liver Transplantation, vol. 14, no. 1, pp. 11–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Ward, M. C. Hogan, S. Rossetti et al., “The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein,” Nature Genetics, vol. 30, no. 3, pp. 259–269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. L. F. Onuchic, L. Furu, Y. Nagasawa et al., “PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats,” American Journal of Human Genetics, vol. 70, no. 5, pp. 1305–1317, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Denamur, A. L. Delezoide, and C. Alberti, “Genotype-phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease,” Kidney International, vol. 77, pp. 350–358, 2010. View at Google Scholar
  40. M. Gunay-Aygun, M. Tuchman, E. Font-Montgomery et al., “PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis,” Molecular Genetics and Metabolism, vol. 99, no. 2, pp. 160–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M. C. Hogan, M. D. Griffin, S. Rossetti, V. E. Torres, C. J. Ward, and P. C. Harris, “PKHDL1, a homolog of the autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte expression,” Human Molecular Genetics, vol. 12, no. 6, pp. 685–698, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. C. J. Ward, D. Yuan, T. V. Masyuk et al., “Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia,” Human Molecular Genetics, vol. 12, no. 20, pp. 2703–2710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Igarashi, X. Shao, B. T. McNally, and T. Hiesberger, “Roles of HNF-1β in kidney development and congenital cystic diseases,” Kidney International, vol. 68, no. 5, pp. 1944–1947, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. L. F. C. Menezes, Y. Cai, Y. Nagasawa et al., “Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm,” Kidney International, vol. 66, no. 4, pp. 1345–1355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Z. Zhang, W. Mai, C. Li et al., “PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2311–2316, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Dorn, L. F. Menezes, G. Mikuz, H. F. Otto, L. F. Onuchic, and C. Sergi, “Immunohistochemical detection of polyductin and co-localization with liver progenitor cell markers during normal and abnormal development of the intrahepatic biliary system and in adult hepatobiliary carcinomas,” Journal of Cellular and Molecular Medicine, vol. 13, no. 7, pp. 1279–1290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Y. Kaimori, Y. Nagasawa, L. F. Menezes et al., “Polyductin undergoes notch-like processing and regulated release from primary cilia,” Human Molecular Genetics, vol. 16, no. 8, pp. 942–956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Hiesberger, E. Gourley, A. Erickson et al., “Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 34357–34364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Wang, J. Zhang, S. M. Nauli et al., “Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia,” Molecular and Cellular Biology, vol. 27, no. 8, pp. 3241–3252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Katsuyama, T. Masuyama, I. Komura, T. Hibino, and H. Takahashi, “Characterization of a novel polycystic kidney rat model with accompanying polycystic liver,” Experimental Animals, vol. 49, no. 1, pp. 51–55, 2000. View at Google Scholar · View at Scopus
  51. Y. Sato, K. Harada, K. Kizawa et al., “Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease,” American Journal of Pathology, vol. 166, no. 1, pp. 49–60, 2005. View at Google Scholar · View at Scopus
  52. M. A. Muff, T. V. Masyuk, A. J. Stroope et al., “Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease,” Laboratory Investigation, vol. 86, no. 9, pp. 940–950, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Yoshihara, H. Kurahashi, M. Morita et al., “PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease,” American Journal of Physiology, vol. 300, pp. F465–F474, 2011. View at Google Scholar
  54. V. E. Torres, W. E. Sweeney Jr., X. Wang et al., “Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats,” Kidney International, vol. 66, no. 5, pp. 1766–1773, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. T. V. Masyuk, A. I. Masyuk, V. E. Torres, P. C. Harris, and N. F. Larusso, “Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate,” Gastroenterology, vol. 132, no. 3, pp. 1104–1116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Banales, T. V. Masyuk, S. A. Gradilone, A. I. Masyuk, J. F. Medina, and N. F. LaRusso, “The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD),” Hepatology, vol. 49, no. 1, pp. 160–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Masyuk, A. Masyuk, and N. LaRusso, “MicroRNAs in cholangiociliopathies,” Cell Cycle, vol. 8, no. 9, pp. 1324–1328, 2009. View at Google Scholar · View at Scopus
  58. S. B. Mason, Y. Liang, R. M. Sinders et al., “Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD,” Anatomical Record, vol. 293, pp. 1279–1288, 2010. View at Google Scholar
  59. J. M. Banales, T. V. Masyuk, P. S. Bogert et al., “Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease,” American Journal of Pathology, vol. 173, no. 6, pp. 1637–1646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. I. Masyuk, T. V. Masyuk, and N. F. LaRusso, “Cholangiocyte primary cilia in liver health and disease,” Developmental Dynamics, vol. 237, no. 8, pp. 2007–2012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. T. V. Masyuk, B. Q. Huang, A. I. Masyuk et al., “Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease,” American Journal of Pathology, vol. 165, no. 5, pp. 1719–1730, 2004. View at Google Scholar · View at Scopus
  62. T. V. Masyuk, B. Q. Huang, C. J. Ward et al., “Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat,” Gastroenterology, vol. 125, no. 5, pp. 1303–1310, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. S. A. Gradilone, T. V. Masyuk, B. Q. Huang et al., “Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD,” Gastroenterology, vol. 139, no. 1, article e302, pp. 304–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Fliegauf, T. Benzing, and H. Omran, “When cilia go bad: cilia defects and ciliopathies,” Nature Reviews Molecular Cell Biology, vol. 8, no. 11, pp. 880–893, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Masyuk, A. Masyuk, and N. LaRusso, “Cholangiociliopathies: genetics, molecular mechanisms and potential therapies,” Current Opinion in Gastroenterology, vol. 25, no. 3, pp. 265–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Ikeda, M. Sasaki, A. Ishikawa et al., “Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture,” Laboratory Investigation, vol. 87, no. 6, pp. 559–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Sato, K. Harada, S. Ozaki et al., “Cholangiocytes with mesenchymal features contribute to progressive hepatic fibrosis of the polycystic kidney rat,” American Journal of Pathology, vol. 171, no. 6, pp. 1859–1871, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Togawa, K. Nakanishi, H. Mukaiyama et al., “Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease,” American Journal of Physiology, vol. 300, pp. F511–F520, 2011. View at Google Scholar
  69. M. Goto, N. Hoxha, R. Osman, J. Wen, R. G. Wells, and K. M. Dell, “Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 50, pp. 639–644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. B. L. Blazer-Yost, J. Haydon, and T. Eggleston-Gulyas, “Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease,” PPAR Research, Article ID 274376, 2010. View at Google Scholar
  71. W. E. Sweeney, R. O. Von Vigier, P. Frost, and E. D. Avner, “Src inhibition ameliorates polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1331–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. V. H. Gattone, X. Wang, P. C. Harris, and V. E. Torres, “Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist,” Nature Medicine, vol. 9, no. 10, pp. 1323–1326, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. X. Wang, V. Gattone, P. C. Harris, and V. E. Torres, “Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 846–851, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Nagao, K. Nish II, M. Katsuyama et al., “Increased water intake decreases progression of polycystic kidney disease in the PCK rat,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2220–2227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Jia, M. Kwon, H. L. Liang et al., “Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease,” Pediatric Nephrology, vol. 25, no. 6, pp. 1139–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Park, W. E. Sweeney Jr., G. Jia et al., “Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD,” American Journal of Physiology, vol. 296, no. 3, pp. F575–F582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Wang, P. C. Harris, S. Somlo, D. Batlle, and V. E. Torres, “Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 526–534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. Sato, K. Harada, S. Furubo et al., “Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib,” American Journal of Pathology, vol. 169, no. 4, pp. 1238–1250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Renken, D. C. Fischer, G. Kundt, N. Gretz, and D. Haffner, “Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats,” Nephrology Dialysis Transplantation, vol. 26, pp. 92–100, 2010. View at Google Scholar